MedTrace Logo

The Screening Protocol for The VIKTORY Trial

NCT02299648 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 651

Last updated 2022-06-15

No results posted yet for this study

Summary

This protocol is a screening protocol only. No drug intervention study will be included in this protocol. However, based on the molecular profiling, patients may be eligible for targeted agents. However, the molecular profiling doesn't guarantee the enrollment onto the clinical trial. Currently, the available drugs are AKT inhibitor, MEK inhibitor, Wee1 inhibitor, MET inhibitor. ATR inhibitor and other agents may be available in the context of clinical trials depending on the availability.

Conditions

  • Stomach Neoplasms

Interventions

OTHER

Molecular profiling

molecular profiling, patient derived cells, fresh or FFPE

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jeeyun Lee, MD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-25
Primary Completion
2021-12-30
Completion
2022-05-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02299648 on ClinicalTrials.gov